Bide Pharmatech (SH:688073) Xin Lang Zheng Quan·2025-11-05 02:37Core Viewpoint - Bid Pharma's stock price has experienced fluctuations, with a year-to-date increase of 44.84% but a recent decline of 12.96% over the past five trading days [1] Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Financial Performance - For the period from January to September 2025, Bid Pharma achieved operating revenue of 979 million yuan, representing a year-on-year growth of 20.67%. The net profit attributable to the parent company was 120 million yuan, with a year-on-year increase of 42.79% [2] - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3] Shareholder Structure - As of September 30, 2025, the number of shareholders for Bid Pharma was 3,493, a decrease of 7.64% from the previous period. The average circulating shares per person increased by 8.27% to 12,377 shares [2] - Notable institutional holdings include: - China Europe Medical Health Mixed A (003095) as the second-largest shareholder with 4.4532 million shares, an increase of 200,700 shares from the previous period - China Europe Medical Innovation Stock A (006228) as a new fourth-largest shareholder with 2.0222 million shares - Other new institutional shareholders include E Fund Value Growth Mixed (110010), ICBC Medical Health Stock (000831), and others [3]